Rob Hopfner, RPh, PhD, MBA| Director
Rob Hopfner, RPh, PhD, MBA, is a Managing Partner at Pivotal bioVentures. Rob is currently on the boards of Iterum Therapeutics, Oculis, and Sutrovax and was formerly either a board member or board observer on Aciex Therapeutics (sold to Nicox S.A.), Civitas Therapeutics (sold to Acorda Therapeutics), Cydan, Dermira (NASDAQ: DERM), Hyperion Therapeutics (sold to Horizon Pharma), Imara Pharmaceuticals, NextWave Pharmaceuticals (sold to Pfizer), Pharmakea Therapeutics, and Vtesse (sold to Sucampo Pharmaceuticals). Other investments where Rob played a significant role included Kezar Life Sciences, Madrigal Pharmaceuticals (NASDAQ: MDGL), Menlo Therapeutics, Merus BV (NASDAQ: MRUS) and Tetraphase Pharmaceuticals (NASDAQ: TTPH).
Rob was previously a Managing Director at Bay City Capital and prior to that worked in business development and investment roles at DuPont Pharmaceuticals and at Ag-West Biotech, respectively. Rob holds a PhD in Pharmacology and a degree in Pharmacy from the University of Saskatchewan, and an MBA from the University of Chicago Booth School of Business. He completed his post-doctoral work at Harvard Medical School. Rob won numerous awards during his research career and he published several articles in top medical journals based on his work.